Analogs of thalidomide as potential angiogenesis inhibitors

US7320991B2 · kind B2 · utility

Assignee

• The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer · US

Inventors

• William D. Figg · Fairfax, US
• Kurt Eger · Leipzig, DE
• Uwe Teubert · Hameln, DE
• Michael Weiss · Moreland Hills, US
• Michael Guetschow · Bonn, DE
• Thomas Hecker · Erfurt, DE
• Sunna Hauschildt · Leipzig, DE

Key dates

• Filing date: Feb 26, 2002
• Grant date: Jan 22, 2008
• Expiry date: Feb 26, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified. In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition of undesirable angiogenesis without the undesirable effects of administration of thalidomide.